119 related articles for article (PubMed ID: 33894403)
1. Pulmonary myeloid cell uptake of biodegradable nanoparticles conjugated with an anti-fibrotic agent provides a novel strategy for treating chronic allergic airways disease.
Chakraborty A; Pinar AA; Lam M; Bourke JE; Royce SG; Selomulya C; Samuel CS
Biomaterials; 2021 Jun; 273():120796. PubMed ID: 33894403
[TBL] [Abstract][Full Text] [Related]
2. Serelaxin improves the therapeutic efficacy of RXFP1-expressing human amnion epithelial cells in experimental allergic airway disease.
Royce SG; Tominaga AM; Shen M; Patel KP; Huuskes BM; Lim R; Ricardo SD; Samuel CS
Clin Sci (Lond); 2016 Dec; 130(23):2151-2165. PubMed ID: 27647937
[TBL] [Abstract][Full Text] [Related]
3. Intranasally administered serelaxin abrogates airway remodelling and attenuates airway hyperresponsiveness in allergic airways disease.
Royce SG; Lim CX; Patel KP; Wang B; Samuel CS; Tang ML
Clin Exp Allergy; 2014 Nov; 44(11):1399-408. PubMed ID: 25113628
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease.
Royce SG; Shen M; Patel KP; Huuskes BM; Ricardo SD; Samuel CS
Stem Cell Res; 2015 Nov; 15(3):495-505. PubMed ID: 26426509
[TBL] [Abstract][Full Text] [Related]
5. iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid.
Royce SG; Mao W; Lim R; Kelly K; Samuel CS
FASEB J; 2019 May; 33(5):6402-6411. PubMed ID: 30768365
[TBL] [Abstract][Full Text] [Related]
6. Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease.
Royce SG; Rele S; Broughton BRS; Kelly K; Samuel CS
FASEB J; 2017 Sep; 31(9):4168-4178. PubMed ID: 28626025
[TBL] [Abstract][Full Text] [Related]
7. Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for allergic airways disease.
Patel KP; Giraud AS; Samuel CS; Royce SG
Br J Pharmacol; 2016 Jun; 173(12):2016-29. PubMed ID: 27060978
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel model incorporating airway epithelial damage and related fibrosis to the pathogenesis of asthma.
Royce SG; Patel KP; Samuel CS
Lab Invest; 2014 Dec; 94(12):1326-39. PubMed ID: 25264707
[TBL] [Abstract][Full Text] [Related]
9. Endogenous relaxin regulates collagen deposition in an animal model of allergic airway disease.
Mookerjee I; Solly NR; Royce SG; Tregear GW; Samuel CS; Tang ML
Endocrinology; 2006 Feb; 147(2):754-61. PubMed ID: 16254028
[TBL] [Abstract][Full Text] [Related]
10. Relaxin reverses airway remodeling and airway dysfunction in allergic airways disease.
Royce SG; Miao YR; Lee M; Samuel CS; Tregear GW; Tang ML
Endocrinology; 2009 Jun; 150(6):2692-9. PubMed ID: 19213838
[TBL] [Abstract][Full Text] [Related]
11. Serelaxin enhances the therapeutic effects of human amnion epithelial cell-derived exosomes in experimental models of lung disease.
Royce SG; Patel KP; Mao W; Zhu D; Lim R; Samuel CS
Br J Pharmacol; 2019 Jul; 176(13):2195-2208. PubMed ID: 30883698
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with relaxin and methylprednisolone augments the effects of either treatment alone in inhibiting subepithelial fibrosis in an experimental model of allergic airways disease.
Royce SG; Sedjahtera A; Samuel CS; Tang ML
Clin Sci (Lond); 2013 Jan; 124(1):41-51. PubMed ID: 22817662
[TBL] [Abstract][Full Text] [Related]
13. Protection from Cigarette Smoke-Induced Lung Dysfunction and Damage by H2 Relaxin (Serelaxin).
Pini A; Boccalini G; Lucarini L; Catarinicchia S; Guasti D; Masini E; Bani D; Nistri S
J Pharmacol Exp Ther; 2016 Jun; 357(3):451-8. PubMed ID: 27048661
[TBL] [Abstract][Full Text] [Related]
14. Relaxin-Loaded Inhaled Porous Microspheres Inhibit Idiopathic Pulmonary Fibrosis and Improve Pulmonary Function Post-Bleomycin Challenges.
Qiu S; Fu X; Shi Y; Zang H; Zhao Y; Qin Z; Lin G; Zhao X
Mol Pharm; 2023 Aug; 20(8):3947-3959. PubMed ID: 37358639
[TBL] [Abstract][Full Text] [Related]
15. Airway remodelling and inflammation in asthma are dependent on the extracellular matrix protein fibulin-1c.
Liu G; Cooley MA; Nair PM; Donovan C; Hsu AC; Jarnicki AG; Haw TJ; Hansbro NG; Ge Q; Brown AC; Tay H; Foster PS; Wark PA; Horvat JC; Bourke JE; Grainge CL; Argraves WS; Oliver BG; Knight DA; Burgess JK; Hansbro PM
J Pathol; 2017 Dec; 243(4):510-523. PubMed ID: 28862768
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor-beta1 suppresses airway hyperresponsiveness in allergic airway disease.
Alcorn JF; Rinaldi LM; Jaffe EF; van Loon M; Bates JH; Janssen-Heininger YM; Irvin CG
Am J Respir Crit Care Med; 2007 Nov; 176(10):974-82. PubMed ID: 17761617
[TBL] [Abstract][Full Text] [Related]
17. Human Recombinant Relaxin (Serelaxin) as Anti-fibrotic Agent: Pharmacology, Limitations and Actual Perspectives.
Sassoli C; Nistri S; Chellini F; Bani D
Curr Mol Med; 2022; 22(3):196-208. PubMed ID: 33687895
[TBL] [Abstract][Full Text] [Related]
18. The leukotriene receptor antagonist pranlukast attenuates airway remodeling by suppressing TGF-β signaling.
Hur J; Kang JY; Rhee CK; Kim YK; Lee SY
Pulm Pharmacol Ther; 2018 Feb; 48():5-14. PubMed ID: 29031615
[TBL] [Abstract][Full Text] [Related]
19. Trefoil factor-2 reverses airway remodeling changes in allergic airways disease.
Royce SG; Lim C; Muljadi RC; Samuel CS; Ververis K; Karagiannis TC; Giraud AS; Tang ML
Am J Respir Cell Mol Biol; 2013 Jan; 48(1):135-44. PubMed ID: 22652198
[TBL] [Abstract][Full Text] [Related]
20. The anti-fibrotic actions of relaxin are mediated through AT
Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
